Opal Wealth Advisors LLC Makes New $26,000 Investment in TransMedics Group, Inc. $TMDX

Opal Wealth Advisors LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 191 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds also recently modified their holdings of TMDX. NBC Securities Inc. acquired a new stake in shares of TransMedics Group during the 1st quarter worth about $25,000. Smartleaf Asset Management LLC boosted its stake in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Quarry LP lifted its holdings in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the period. Hager Investment Management Services LLC lifted its holdings in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock worth $50,000 after acquiring an additional 205 shares during the period. Finally, CWM LLC lifted its holdings in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after acquiring an additional 155 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a report on Tuesday, June 17th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, August 30th. Finally, Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.40.

TransMedics Group Stock Down 2.6%

TMDX stock opened at $117.43 on Thursday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $160.80. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $4.00 billion, a P/E ratio of 60.84 and a beta of 2.18. The firm has a 50 day simple moving average of $116.15 and a 200-day simple moving average of $108.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.